Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Other Working Capital Changes (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Other Working Capital Changes for 11 consecutive years, with $88000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes changed N/A to $88000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $120689.0, a N/A change, with the full-year FY2025 number at -$37000.0, up 97.8% from a year prior.
  • Other Working Capital Changes was $88000.0 for Q4 2025 at Crescent Biopharma, up from $25971.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.4 million in Q3 2021 to a low of -$1.9 million in Q4 2021.
  • A 5-year average of -$164842.1 and a median of -$2626.5 in 2024 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: surged 292.54% in 2022, then tumbled 1161.31% in 2023.
  • Crescent Biopharma's Other Working Capital Changes stood at -$1.9 million in 2021, then soared by 86.01% to -$261549.0 in 2022, then tumbled by 131.14% to -$604542.0 in 2023, then soared by 98.02% to -$11971.0 in 2024, then skyrocketed by 835.11% to $88000.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Other Working Capital Changes are $88000.0 (Q4 2025), $25971.0 (Q2 2025), and $6718.0 (Q1 2025).